Pharmacists in the emergency department play a crucial role in upfront decision making around medicines for patients presenting with various medical conditions.
Cristina Roman, is the Lead Pharmacist at Alfred Emergency Trauma Centre. In her 12 years working in the Emergency Department, Cristina has established pharmacy services, and filled gaps in patient care with new models of care.
One of those models of care adopted by the US and other countries, is involving pharmacists for critically unwell patients that present to the emergency department.
Through her investigations, Cristina has considered how pharmacy services can impact stroke care, sepsis and trauma outcomes.
Thrombolytic therapy is crucial in ischaemic strokes, as every minute with a blood clot in the brain increases the risk of permanent disability for the patient.
Pharmacists can play a crucial role in identifying patients appropriate for thrombolysis and assisting with the administration of high-risk medications like thrombolysis for stroke patients. This can mean faster thrombolysis to eligible patients, shaping the scope of practice for the emergency medicine pharmacist.
In addition, her studies have also shown the involvement of pharmacists in sepsis calls improves time to antibiotic administration, particularly for patients in ICU care. The evidence has shown better outcomes for the most unwell patients.
Nurses and medical staff at Alfred Hospital are now actively pulling pharmacists into scenarios, highlighting the value and benefit of their involvement in patient care.
This model of care for emergency departments involving pharmacists has gained international interest and is continuing to expand.
Australian Health Journal spoke with Cristina Roman and Lisa Bremner, Advanced Training Resident Pharmacist at Alfred Hospital Emergency Trauma Centre.
-
Pathology technology at a crossroads
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
– Pathology Technology Australia’s key priorities in the coming years
– Current local capability in pathology technology compared to other countries
– How the health system supports change and adoption of pathology technology
– How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
– Observations in the Strengthening Medicare Taskforce ReportIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Changes in MBS bulk billing incentives address GP capacity in women’s health
Dr. Sneha Wadhwani, a General Practitioner in Bondi, and Conjoint Lecturer at UNSW School of Medicine, is actively involved in enhancing women’s health services across Australia. As the Co-founder and Clinical Director of Evoca Women’s Health, she highlights the significant improvements in funding for women’s health, particularly with the new MBS bulk billing incentives, in new codes, that commenced on November 1, 2025.
-
Reflecting on a pivotal year for pharmacy
Dr. Kate Wang, a Senior Lecturer in Pharmacy at RMIT University and Adjunct Senior Lecturer, University of Western Australia, has over a decade of experience in both hospital and community pharmacy settings.
Dr Wang spoke to Australian Health Journal on some of the key topics in 2024 that have been pivotal as a pharmacist, academic and researcher for the pharmacy profession.
